Radical prostatectomy improves survival in selected metastatic prostate cancer patients: A North American population-based study.
North American population
external beam radiation therapy
metastatic prostate cancer
radical prostatectomy
Journal
International journal of urology : official journal of the Japanese Urological Association
ISSN: 1442-2042
Titre abrégé: Int J Urol
Pays: Australia
ID NLM: 9440237
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
28
08
2020
accepted:
04
04
2021
pubmed:
29
5
2021
medline:
14
8
2021
entrez:
28
5
2021
Statut:
ppublish
Résumé
To test whether radical prostatectomy might result in better survival than external beam radiation therapy in metastatic prostate cancer patients. Newly diagnosed metastatic prostate cancer patients with M1a/b substages, treated with radical prostatectomy or external beam radiation therapy were abstracted from the Surveillance, Epidemiology and End Results database (2004-2016). Temporal trend analyses, propensity score matching, cumulative incidence plots, multivariate competing risks regression models and landmark analyses were used. Of 4280 patients, 954 (22.3%) were treated with radical prostatectomy. After propensity score matching, 5-year cancer-specific mortality was 47.0 versus 53.0% in radical prostatectomy versus external beam radiation therapy patients (P = 0.003). In propensity score matched competing risks regression models, radical prostatectomy was associated with lower cancer-specific mortality versus external beam radiation therapy (hazard ratio 0.79, 95% confidence interval 0.79-0.90; P = 0.001). Finally, landmark analyses rejected the bias favoring radical prostatectomy. Finally, in subgroup analyses, we relied on selection criteria that most closely resembled the STAMPEDE criteria and a similar hazard ratio of 0.8 (P < 0.001) was recorded. In metastatic prostate cancer, radical prostatectomy results in lower cancer-specific mortality relative to external beam radiation therapy. Even after adjustment for age at diagnosis, prostate-specific antigen and biopsy Gleason grade grouping, lower cancer-specific mortality rates are recorded in radical prostatectomy patients than in external beam radiation therapy patients. As a result, radical prostatectomy should be considered as a treatment option in selected metastatic prostate cancer patients. However, further validation will be provided by ongoing clinical trials.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
834-839Informations de copyright
© 2021 The Authors. International Journal of Urology published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association.
Références
Mohler JL, Higano CS, Pugh TJ. NCCN Guidelines Index Table of Contents Discussion. Prostate Cancer. Published online 2019; 166: MS-22.
Sweeney CJ, Chen Y-H, Carducci M et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 2015; 373: 737-46.
Parker CC, James ND, Brawley CD et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 2018; 392: 2353-66.
Knipper S, Beyer B, Mandel P et al. Outcome of patients with newly diagnosed prostate cancer with low metastatic burden treated with radical prostatectomy: a comparison to STAMPEDE arm H. World J. Urol. 2020; 38: 1459-64.
Sooriakumaran P, Karnes J, Stief C et al. A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation. Eur. Urol. 2016; 69: 788-94.
Pompe RS, Tilki D, Preisser F et al. Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages. Prostate 2018; 78: 753-7.
Leyh-Bannurah S-R, Gazdovich S, Budäus L et al. Local therapy improves survival in metastatic prostate cancer. Eur. Urol. 2017; 72: 118-24.
Löppenberg B, Dalela D, Karabon P et al. The impact of local treatment on overall survival in patients with metastatic prostate cancer on diagnosis: a national cancer data base analysis. Eur. Urol. 2017; 72: 14-9.
About the SEER Program. SEER. [Cited 11 Sep 2019.] Available from URL: https://seer.cancer.gov/about/overview.html
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann. Surg. Oncol. 2010; 17: 1471-4.
Fizazi K, Tran N, Fein L et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 2017; 377: 352-60.
Knipper S, Dzyuba-Negrean C, Palumbo C et al. External beam radiation therapy improves survival in high- and intermediate-risk non-metastatic octogenarian prostate cancer patients. Int. Urol. Nephrol. 2020; 52: 59-66.
Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar. Behav. Res. 2011; 46: 399-424.
Hanna N, Trinh Q-D, Seisen T et al. Effectiveness of neoadjuvant chemotherapy for muscle-invasive bladder cancer in the current real world setting in the USA. Eur. Urol. Oncol. 2018; 1: 83-90.
Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. Am. J. Epidemiol. 2009; 170: 244-56.
Williams SB, Kamat AM, Chamie K et al. Systematic review of comorbidity and competing-risks assessments for bladder cancer patients. Eur. Urol. Oncol. 2018; 1: 91-100.
Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J. Clin. Oncol. 1983; 1: 710-9.
Team RC. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2012. Published online 2018. Available from URL: http://www.R-project.org
Ovarian.pdf. [Cited 9 Dec 2019.] Available from URL: https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf
Venook AP. NCCN Guidelines Index Table of Contents Discussion. Published online 2019; 186.
Satkunasivam R, Kim AE, Desai M et al. Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-medicare analysis. J. Urol. 2015; 194: 378-85.
Gratzke C, Engel J, Stief CG. Role of radical prostatectomy in metastatic prostate cancer: data from the munich cancer registry. Eur. Urol. 2014; 66: 602-3.
Mazzone E, Preisser F, Nazzani S et al. Location of metastases in contemporary prostate cancer patients affects cancer-specific mortality. Clin. Genitourin. Cancer 2018; 16: 376-384.e1.
Bandini M, Preisser F, Nazzani S et al. The effect of other-cause mortality adjustment on access to alternative treatment modalities for localized prostate cancer among African American Patients. Eur. Urol. Oncol. 2018; 1: 215-22.
Stolzenbach LF, Deuker M, Collà-Ruvolo C et al. External beam radiation therapy improves survival in low-volume metastatic prostate cancer patients: a North American population-based study. Prostate Cancer Prostatic Dis. 2021; 24: 253-60.
Abdollah F, Sun M, Thuret R et al. A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006. Eur. Urol. 2011; 59: 88-95.
Dell'Oglio P, Boehm K, Trudeau V et al. Survival after conservative management versus external beam radiation therapy in elderly patients with localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2016; 96: 1037-45.